BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2022 9:00:24 AM | Browse: 309 | Download: 632
 |
Received |
|
2021-10-31 03:52 |
|
Peer-Review Started |
|
2021-10-31 03:53 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-07 02:03 |
|
Revised |
|
2022-04-10 06:51 |
|
Second Decision |
|
2022-05-11 03:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-12 19:44 |
|
Articles in Press |
|
2022-05-12 19:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-03 00:12 |
|
Typeset the Manuscript |
|
2022-06-16 01:01 |
|
Publish the Manuscript Online |
|
2022-06-24 09:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuan-Yuan Hao, Pan-Pan Chen, Xiang-Gui Yuan, Ai-Qi Zhao, Yun Liang, Hui Liu and Wen-Bin Qian |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wen-Bin Qian, MD, PhD, Doctor, Doctor, Professor, Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. qianwb@zju.edu.cn |
| Key Words |
Chimeric antigen receptor T cell therapy; Diffuse large B-cell lymphoma; Immunotherapy; PD-1 inhibitor; Histone deacetylase inhibitor; Case report |
| Core Tip |
We used histone deacetylase inhibitor chidamide combined with PD-1 blockade sintilimab for 7 patients with diffuse large B-cell lymphoma progressing after CART therapy. There are 2 complete response rates (CRs) and 2 PRs during this novel therapy, with an overall response rates of 57.1%, and one patient had a durable CR that lasted at least 20 mo. |
| Publish Date |
2022-06-24 09:00 |
| Citation |
Hao YY, Chen PP, Yuan XG, Zhao A, Liang Y, Liu H, Qian W. Histone deacetylase inhibitor chidamide and PD-1 blockade combination in diffuse large B-cell lymphoma progressing after CD19-targeting chimeric antigen receptor T cells therapy. World J Clin Cases 2022; 10(19): 6555-6562 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i19/6555.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i19.6555 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
